⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 20, 2024Future Oncology

Real-world clinical outcomes among patients with metastatic castration-sensitive prostate cancer initiating apalutamide

Benjamin Lowentritt Shawn Du Carmine Rossi Erik Muser Ibrahim Khilfeh Frédéric Kinkead Jill Korsiak Patrick Lefebvre Dominic Pilon Neeraj Agarwal

View Full Paper

Ask AI

Bookmark

Share

Abstract

To describe overall survival, time to castration resistance and castration resistance-free survival in patients with metastatic castration-sensitive prostate cancer (mCSPC) initiating apalutamide in a US oncology network.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lowentritt et al. (2024) studied this question.

synapsesocial.com/papers/68e69377b6db64358761aa37 https://doi.org/10.1080/14796694.2024.2343647

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Real-World Clinical Outcomes and Treatment Patterns Among Black and Non-Black Patients With Prostate Cancer Initiated on Apalutamide in a Urology Setting2024 · 2 citations
2Real-World Clinical Outcomes and Treatment Patterns Among Black and Non-Black Patients With Prostate Cancer Initiated on Apalutamide in a Urology Setting2024
3Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study2024 · 4 citations
4IUC26661-86 Real-world outcomes in patients with Metastatic Hormone-Sensitive Prostate Cancer treated with androgen deprivation therapy and Apalutamide - A single centre studyClinical Trial · 2026
5Cancer-control outcomes of patients with metastatic hormone-sensitive prostate cancer and ≥ 10 bone metastases receiving apalutamide: a real-world cohortClinical Trial · 2026 · 2 citations